W
WAVEMAN · COMPANY
DYAI · Dyadic International Inc
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

DYAI

DYADIC INTERNATIONAL INC
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001213809
FORM 144 · 1☆ WATCH
INSIDER NET · 180D
-$125.0K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
-11.6%
XBRL, annual
NET MARGIN
-238.3%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$125.0K over 180 days
-$125.0K over 90 days · -$125.0K of it by a 10%+ holder
more than 54% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
-11.6% year over year
below 71% of Pharma & Biotech
MARGIN
-238.3% net margin
below 74% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
0.1% of shares outstanding short · 1.0 days to cover · settled 2026-07-31
below 86% of Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -47.4%
-47.4%12M
-47%-13%+21%+55%2025-092025-102025-122026-032026-052026-072026-09 2026-07-23 · Francisco Trust under agreement dated February 28, 1996 sold $71.3K2026-07-22 · Francisco Trust under agreement dated February 28, 1996 sold $50.5K2026-07-24 · Francisco Trust under agreement dated February 28, 1996 sold $3.2K2026-07-21 · Francisco Trust under agreement dated February 28, 1996 filed to sell $539.3K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $125.0K sold by insiders over 180 days, $539.3K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, DYADIC INTERNATIONAL INC insiders sold a net $125.0K of stock across 18 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Francisco Trust under agreement dated February 28, 1996
—
SELL
2026-07-24
2,616.0
$3.2K
Francisco Trust under agreement dated February 28, 1996
—
SELL
2026-07-23
54,760.0
$71.3K
Francisco Trust under agreement dated February 28, 1996
—
SELL
2026-07-22
38,016.0
$50.5K
Hazelton Joseph P
President and COO
BUY
2025-08-01
26,000.0
$24.7K
Francisco Trust under agreement dated February 28, 1996
—
SELL
2025-01-07
15,000.0
$30.2K
18 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 13 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Francisco Trust under agreement dated February 28, 1996
FILED 2026-07-21
$539.3K
Executive pay vs shareholder return · Mark Emalfarb
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$1.0M
$518.5K
$448.2K
-24%
—
2024
$1.0M
$1.1M
$448.7K
-60%
—
2023
$1.0M
$1.1M
$424.9K
-70%
—
2022
$1.4M
-$435.9K
$466.0K
-77%
—
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$3.1M$3.5M$2.9M$2.9M
OPERATING INCOME$-7.2M$-5.9M$-8.2M$-10.2M
NET INCOME$-7.4M$-5.8M$-6.8M$-9.7M
EPS (DILUTED)-0.23-0.20——
OPERATING CASH FLOW$-5.7M$-4.0M$-6.7M$-8.1M
CASH$4.6M$6.5M$6.5M$5.8M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →